This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Obstructive sleep apnea (OSA) affects an estimated 1 billion people worldwide, yet fewer than 30% of diagnosed patients consistently use CPAP — the standard treatment. The massive GLP-1 drug revolution has now directly intersected with OSA: tirzepatide (Zepbound) received FDA approval specifically for OSA in 2024, marking the first drug approved for this indication. In parallel, hypoglossal nerve stimulation has expanded beyond the pioneering Inspire device, and combination pharmacotherapy is emerging as an approach for patients where anatomy alone doesn't explain their OSA severity.
Tirzepatide for OSA: The SURMOUNT-OSA Trials
Tirzepatide (Zepbound/Mounjaro, Eli Lilly) is a dual GLP-1/GIP receptor agonist that produces average weight loss of 20–22% of body weight in clinical trials — greater than any previous non-surgical intervention. Since obesity is the primary modifiable risk factor for OSA (excess pharyngeal fat narrows the airway), dramatic weight loss was expected to substantially reduce OSA severity.
The SURMOUNT-OSA Phase 3 program consisted of two trials: one in OSA patients not using CPAP, and one in patients using CPAP. Both trials showed tirzepatide reduced the apnea-hypopnea index (AHI — the number of breathing interruptions per hour of sleep) by approximately 25–30 events/hour — representing 55–63% reductions from baseline. Many patients achieved AHI below 5 (normal) or below 15 (mild) from severe baseline values. Oxygen saturation improved, and patient-reported sleep quality and daytime functioning improved significantly. The FDA approved tirzepatide (Zepbound) specifically for moderate-to-severe OSA in adults with obesity in June 2024 — the first OSA drug approval in the drug's history.
Current trials are evaluating tirzepatide and semaglutide in OSA patients with different obesity phenotypes, in combination with CPAP, and in patients with central sleep apnea components.
Hypoglossal Nerve Stimulation: Beyond Inspire
Inspire Medical Systems' upper airway stimulation (UAS) device stimulates the hypoglossal nerve (which controls tongue protrusion) in synchrony with each breath, keeping the airway open during sleep. The STAR trial demonstrated 68% reduction in AHI at 12 months and durable efficacy at 5 years. Inspire received FDA approval in 2014 and is now widely used for CPAP-intolerant patients with OSA.
In 2026, multiple next-generation HNS devices are in trials:
Nyxoah Genio: A totally implantable bilateral hypoglossal nerve stimulator that does not require a chest-implanted pulse generator or external remote — just a small chin-placed neurostimulator chip. The DREAM trial showed the Genio achieved similar AHI reductions to Inspire, and the device is approved in Europe. FDA approval is anticipated based on the BETTER SLEEP trial currently enrolling in the US.
LinguaFlex and Stimuloose: Early-stage implantable and non-implantable tongue muscle stimulation approaches are in Phase 1/2 feasibility trials for patients who are not candidates for surgical implantation.
Research is also investigating expanded eligibility criteria for Inspire — currently restricted to patients without complete concentric palatal collapse (detected by drug-induced sleep endoscopy). Trials of palatal procedures combined with HNS are exploring whether AHI eligibility can be extended.
Combination Drug Therapy for Non-Obese OSA
Not all OSA is simply anatomical. Approximately 30–40% of OSA patients have a significant non-anatomical component — including reduced upper airway muscle responsiveness during sleep, low arousal threshold (waking at minimal respiratory events), and exaggerated loop gain (unstable ventilatory control system). These "endotypic traits" can explain why some non-obese patients have severe OSA and why weight loss alone doesn't eliminate OSA for many patients.
A combination of oxygen + eszopiclone (a sedative that raises arousal threshold) was shown in a landmark 2021 study to reduce AHI by ~15 events/hour in patients with high loop gain — a proof of concept that pharmacological targeting of non-anatomical traits can reduce OSA. Phase 2 trials are now testing:
Atomoxetine + oxybutynin (AD109): This combination increases upper airway muscle tone via noradrenergic stimulation (atomoxetine) while reducing reflex airway narrowing (oxybutynin). The Phase 2 MARIPOSA trial showed ~50% reduction in AHI in selected patients. Apnimed's Phase 3 MARIPOSA-2 trial is recruiting.
Dronabinol: A cannabinoid that stabilizes upper airway muscle tone. Phase 2 results showed AHI reductions of ~10 events/hour. Larger Phase 3 trials are planned.
Key Takeaways
- Tirzepatide (Zepbound) is FDA-approved for OSA in adults with obesity — the first drug approval for this indication — with 55–63% AHI reductions in SURMOUNT-OSA trials.
- Hypoglossal nerve stimulation (Inspire) has 5-year data showing durable efficacy; next-generation devices (Nyxoah Genio) are in US trials to expand this option.
- Atomoxetine + oxybutynin targets non-anatomical OSA traits (muscle tone, arousal threshold) — Phase 3 MARIPOSA-2 is enrolling for patients with endotypic OSA.
- GLP-1 drugs are being studied in combination with CPAP and in central sleep apnea to understand whether benefits extend beyond weight-related airway anatomy.
- OSA endotyping — identifying which physiological traits drive a patient's apnea — is becoming a tool to match patients to the most likely effective therapy.